Myovant Sciences Cash on Hand 2017-2022 | MYOV
Myovant Sciences cash on hand from 2017 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Myovant Sciences Annual Cash on Hand (Millions of US $) |
2022 |
$434 |
2021 |
$685 |
2020 |
$80 |
2019 |
$156 |
2018 |
$109 |
2017 |
$181 |
2016 |
$ |
Myovant Sciences Quarterly Cash on Hand (Millions of US $) |
2022-03-31 |
$434 |
2021-12-31 |
$528 |
2021-09-30 |
$616 |
2021-06-30 |
$570 |
2021-03-31 |
$685 |
2020-12-31 |
$746 |
2020-09-30 |
$111 |
2020-06-30 |
$100 |
2020-03-31 |
$80 |
2019-12-31 |
$99 |
2019-09-30 |
$158 |
2019-06-30 |
$227 |
2019-03-31 |
$156 |
2018-12-31 |
$183 |
2018-09-30 |
$154 |
2018-06-30 |
$144 |
2018-03-31 |
$109 |
2017-12-31 |
$129 |
2017-09-30 |
$129 |
2017-06-30 |
$154 |
2017-03-31 |
$181 |
2016-12-31 |
$192 |
2016-09-30 |
$0 |
2016-06-30 |
|
2016-03-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$1.236B |
$0.231B |
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|